PL369526A1 - Związki hamujące zapalenie - Google Patents

Związki hamujące zapalenie

Info

Publication number
PL369526A1
PL369526A1 PL02369526A PL36952602A PL369526A1 PL 369526 A1 PL369526 A1 PL 369526A1 PL 02369526 A PL02369526 A PL 02369526A PL 36952602 A PL36952602 A PL 36952602A PL 369526 A1 PL369526 A1 PL 369526A1
Authority
PL
Poland
Prior art keywords
pro
derivatives
interleukin
thr
receptors
Prior art date
Application number
PL02369526A
Other languages
English (en)
Other versions
PL221492B1 (pl
Inventor
Thomas Luger
Original Assignee
Thomas Luger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Luger filed Critical Thomas Luger
Publication of PL369526A1 publication Critical patent/PL369526A1/pl
Publication of PL221492B1 publication Critical patent/PL221492B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C12N2501/86—Melanocyte-stimulating hormone [MSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL369526A 2001-02-14 2002-02-08 Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie PL221492B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106852A DE10106852A1 (de) 2001-02-14 2001-02-14 Entzündungshemmende Verbindungen

Publications (2)

Publication Number Publication Date
PL369526A1 true PL369526A1 (pl) 2005-05-02
PL221492B1 PL221492B1 (pl) 2016-04-29

Family

ID=7674019

Family Applications (3)

Application Number Title Priority Date Filing Date
PL369526A PL221492B1 (pl) 2001-02-14 2002-02-08 Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie
PL391988A PL223478B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym
PL391884A PL223229B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL391988A PL223478B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym
PL391884A PL223229B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń

Country Status (17)

Country Link
US (4) US8003608B2 (pl)
EP (6) EP2260843A3 (pl)
JP (1) JP4259870B2 (pl)
CN (3) CN1269477C (pl)
AT (2) ATE502632T1 (pl)
AU (2) AU2002253000B2 (pl)
CA (1) CA2437788C (pl)
CY (4) CY1106563T1 (pl)
DE (3) DE10106852A1 (pl)
DK (4) DK1749524T3 (pl)
ES (4) ES2427970T3 (pl)
MX (1) MXPA03007255A (pl)
NZ (2) NZ542406A (pl)
PL (3) PL221492B1 (pl)
PT (4) PT2196202E (pl)
SI (4) SI2196202T1 (pl)
WO (1) WO2002064131A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
CA2447629A1 (en) * 2001-05-25 2002-12-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw The lectin-like domain of thrombomodulin and its therapeutic use
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
WO2006046746A1 (ja) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. 内臓痛予防・治療剤
WO2007004613A1 (ja) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
EP1782819A1 (en) * 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
DE102006003854A1 (de) * 2006-01-26 2007-08-02 Universität Duisburg-Essen Regulatorische und cytotoxische CD8+ T-Zellen
CA2703891A1 (en) * 2007-11-19 2009-05-28 Universitaetsklinikum Muenster Compositions for reducing oxidative stress and uses thereof
WO2013041719A1 (en) * 2011-09-23 2013-03-28 Westfaelische Wilhelms-Universitaet Muenster Tripeptide kdpt for antiapoptotic treatment
KR20140136494A (ko) 2012-03-20 2014-11-28 헬릭스 바이오메딕스, 인코포레이티드 짧은 항균 지질펩티드
CA2910196A1 (en) * 2013-05-10 2014-11-13 Southern Research Institute Compounds, compositions and methods for the treatment of diseases through inhibiting tgf-beta activity
AU2014323008B2 (en) 2013-09-23 2018-02-08 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
EP3065756B1 (en) 2013-11-07 2019-02-20 Dr. August Wolff GmbH & Co. KG Arzneimittel Storage stable lyophilized tripeptide formulations
CN107349416A (zh) * 2017-08-01 2017-11-17 中山大学 一种含三肽化合物的抗骨关节炎药物
EP3682892A4 (en) * 2017-09-15 2021-10-27 Kine Sciences Co., Ltd. USE OF PEPTIDES AS A THERAPEUTIC AGENT AGAINST AUTOIMMUNE AND BONE DISEASES
CN111150831B (zh) * 2020-02-27 2023-06-09 广州领晟医疗科技有限公司 多肽KdPT的应用
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN114432421B (zh) * 2022-01-12 2024-04-12 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的KdPT多肽及其应用
CN114404562A (zh) * 2022-01-17 2022-04-29 广州领晟医疗科技有限公司 一种用于治疗骨关节炎的KdPT多肽及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU604751B2 (en) 1986-08-08 1991-01-03 Board Of Regents, The University Of Texas System Anti-inflammatory peptides
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
JP2633369B2 (ja) * 1988-03-28 1997-07-23 ブリティッシュ・テクノロジー・グループ・リミテッド ペプチド
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
DE3844046A1 (de) * 1988-12-28 1990-07-05 Hoerrmann Wilhelm Arzneimittel, die isomere des hydroxylysins oder lysins enthalten
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
NZ261449A (en) * 1993-01-22 1996-08-27 Pfizer Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1- carboxamide and pharmaceutical compositions thereof
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
SE9500270L (sv) * 1995-01-25 1996-09-09 A K J Medi Konsult Ab Läkemedel mot bristtillstånd
AU4861196A (en) * 1995-02-03 1996-08-21 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
JP3567350B2 (ja) * 1996-03-13 2004-09-22 株式会社ホーネンコーポレーション 抗脱毛症剤
JP3922594B2 (ja) 1996-03-19 2007-05-30 株式会社ノエビア 抗菌性低刺激化粧料
CA2256669A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6297283B1 (en) * 1996-10-11 2001-10-02 Kowa Co., Ltd. Diamide compounds and compositions containing the same
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
JP3962166B2 (ja) * 1998-10-19 2007-08-22 株式会社資生堂 皮膚外用剤
AU1773600A (en) * 1998-12-21 2000-07-12 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
CA2359636A1 (en) * 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000054750A1 (fr) * 1999-03-15 2000-09-21 Dmitry Anatolievich Starchenko Procede de correction des perturbations dans la synthese du collagene et substance bioactive de mise en oeuvre de ce procede
US7169603B2 (en) * 2000-07-14 2007-01-30 Mgi Pharma Biologics, Inc. α-MSH related compounds and methods of use
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
US7960508B2 (en) 2001-05-11 2011-06-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity

Also Published As

Publication number Publication date
CY1106563T1 (el) 2012-01-25
EP1427405B1 (de) 2007-04-04
CN1269477C (zh) 2006-08-16
ES2411935T3 (es) 2013-07-09
PL391988A1 (pl) 2010-09-13
HK1140915A1 (zh) 2010-10-29
EP1427405A2 (de) 2004-06-16
PL221492B1 (pl) 2016-04-29
US8003608B2 (en) 2011-08-23
HK1061980A1 (en) 2004-12-10
MXPA03007255A (es) 2005-02-14
AU2002253000B2 (en) 2006-05-25
EP2198723A1 (de) 2010-06-23
SI1749524T1 (sl) 2011-08-31
ES2427970T3 (es) 2013-11-05
CA2437788C (en) 2011-04-05
DK2196202T3 (da) 2013-09-08
US20040077552A1 (en) 2004-04-22
US20150087578A1 (en) 2015-03-26
PT2196202E (pt) 2013-09-24
AU2006203622A1 (en) 2006-09-07
DK1749524T3 (da) 2011-06-06
HK1140960A1 (en) 2010-10-29
ES2361422T3 (es) 2011-06-16
JP2004533995A (ja) 2004-11-11
ATE358475T1 (de) 2007-04-15
PL391884A1 (pl) 2010-09-13
PT1427405E (pt) 2007-05-31
CA2437788A1 (en) 2002-08-22
DK2198723T3 (da) 2013-06-17
NZ542406A (en) 2007-04-27
WO2002064131A2 (de) 2002-08-22
DE10106852A1 (de) 2002-09-05
ATE502632T1 (de) 2011-04-15
CY1114214T1 (el) 2016-08-31
AU2006203622B2 (en) 2007-08-09
SI2196202T1 (sl) 2013-09-30
EP2198723B1 (de) 2013-04-10
NZ528191A (en) 2005-11-25
CN101215544B (zh) 2011-05-04
EP2260843A2 (de) 2010-12-15
US9550807B2 (en) 2017-01-24
DK1427405T3 (da) 2007-07-02
EP2196202B1 (de) 2013-07-17
JP4259870B2 (ja) 2009-04-30
EP1749524A2 (de) 2007-02-07
PT2198723E (pt) 2013-06-12
CY1111450T1 (el) 2015-08-05
EP2196202A1 (de) 2010-06-16
PL223478B1 (pl) 2016-10-31
US20170087202A1 (en) 2017-03-30
DE50214981D1 (de) 2011-05-05
CN1541095A (zh) 2004-10-27
EP1749524A3 (de) 2007-11-28
EP2189156A1 (de) 2010-05-26
US10046020B2 (en) 2018-08-14
HK1095538A1 (en) 2007-05-11
CN101215544A (zh) 2008-07-09
DE50209873D1 (de) 2007-05-16
CN101810847A (zh) 2010-08-25
WO2002064131A3 (de) 2004-04-01
SI2198723T1 (sl) 2013-06-28
CN101810847B (zh) 2013-02-13
EP2260843A3 (de) 2011-08-03
CY1114024T1 (el) 2016-07-27
SI1427405T1 (sl) 2007-08-31
PL223229B1 (pl) 2016-10-31
US8846617B2 (en) 2014-09-30
US20120045462A1 (en) 2012-02-23
ES2281511T3 (es) 2007-10-01
EP1749524B1 (de) 2011-03-23
PT1749524E (pt) 2011-05-25

Similar Documents

Publication Publication Date Title
PL369526A1 (pl) Związki hamujące zapalenie
Zhang et al. Effects of Crocus sativus L. on the ethanol-induced impairment of passive avoidance performances in mice
Mendelson et al. Effects of melatonin and propranolol on sleep of the rat
Gonzalez et al. Chronic photodamage in skin of mast cell‐deficient mice
CY1111265T1 (el) Χρηση πεπτιδικων παραγωγων για διεγερση διαφοροποιησης κυτταρου
JPH10513149A (ja) キナゾリノン医薬品及びその利用
Saitou et al. Slow wave sleep-inducing effects of first generation H1-antagonists
EP1392346A2 (en) Composition and method for enhancing elasticity of tissue
CN1154484C (zh) 司来吉兰或去甲基司吉兰在生产治疗创伤、烧伤、光照损害的药物中的用途
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
CA2501738A1 (en) Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
WO2002076381A3 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
ATE374781T1 (de) Derivate von genkwanin und sakuranetin, deren kosmetische und therapeutische verwendung, und verfahren zu deren herstellung
Malo et al. Inhibition by auranofin of pharmacologic and antigen-induced contractions of the isolated guinea pig trachea
NO20005131L (no) Nye behandlinger for nervøse forstyrrelser
WO1999000079A1 (en) Skin aging and wound treatment using cell migration agents
RU99108220A (ru) Способ лечения острого периода гипоталамического синдрома пубертатного периода
BRPI0507182A (pt) uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados
WO1987000431A1 (en) Use of gallopamil for treating bronchospastic airway diseases
RU94010369A (ru) Способ получения производных инсулина
Lepistö et al. Stimulation of wound healing by the immunomodulator LS-2616 (Linomide)
Nakamoto et al. Effect of allergen immunotherapy on nasal responses in guinea‐pigs with allergic rhinitis
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
Chan et al. Early release of mitochondrial cytochrome c and the subsequent activation of caspase-3 are involved in the apoptotic death of neonatal motoneurons after injury
Tanaka et al. Evaluation of an antiallergic agent (disodium cromoglycate) in rat conjunctiva using monoclonal IgE antibody

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 391989

Country of ref document: PL

Kind code of ref document: A1